Chongqing Pharscin Pharmaceutical Co Ltd Net Asset Quality Index
Chongqing Pharscin Pharmaceutical Co Ltd net asset quality index. Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a Net Asset Quality Index of 85.6% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.00 Billion minus total liabilities of CN¥287.66 Million yields net assets of CN¥1.71 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Chongqing Pharscin Pharmaceutical Co Ltd (002907) shareholders funds for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)
Net asset quality index of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 85.6%, representing net assets of CN¥1.71 Billion against total assets of CN¥2.00 Billion CNY. Check 002907 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Chongqing Pharscin Pharmaceutical Co Ltd Net Asset Quality Index by Year (2013–2024)
Chongqing Pharscin Pharmaceutical Co Ltd net asset quality index by year from 2013 to 2024. The table below presents the year-by-year Net Asset Quality Index for Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 002907 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 86.6% | CN¥1.66 Billion | CN¥1.92 Billion | CN¥257.55 Million | ▼ -0.8 pp |
| 2023 | 87.4% | CN¥1.62 Billion | CN¥1.85 Billion | CN¥233.53 Million | ▲ +1.1 pp |
| 2022 | 86.3% | CN¥1.61 Billion | CN¥1.87 Billion | CN¥256.28 Million | ▲ +14.8 pp |
| 2021 | 71.5% | CN¥1.27 Billion | CN¥1.77 Billion | CN¥505.56 Million | ▲ +2.8 pp |
| 2020 | 68.7% | CN¥1.18 Billion | CN¥1.72 Billion | CN¥539.59 Million | ▲ +3.3 pp |
| 2019 | 65.4% | CN¥1.07 Billion | CN¥1.64 Billion | CN¥566.67 Million | ▼ -10.4 pp |
| 2018 | 75.8% | CN¥828.91 Million | CN¥1.09 Billion | CN¥264.72 Million | ▼ -5.5 pp |
| 2017 | 81.3% | CN¥719.95 Million | CN¥885.15 Million | CN¥165.20 Million | ▲ +10.6 pp |
| 2016 | 70.7% | CN¥461.42 Million | CN¥652.32 Million | CN¥190.91 Million | ▲ +2.9 pp |
| 2015 | 67.8% | CN¥365.71 Million | CN¥539.29 Million | CN¥173.59 Million | ▲ +12.0 pp |
| 2014 | 55.8% | CN¥299.77 Million | CN¥537.39 Million | CN¥237.62 Million | ▼ -2.2 pp |
| 2013 | 58.0% | CN¥240.97 Million | CN¥415.35 Million | CN¥174.39 Million | — |